As part of a longitudinal study of health and aging, the conditions and motivational factors that prospectively predicted either cessation or reduction in alcohol consumption were compared. Data were from 1,517 community-dwelling men who in 1973 (Time 1) and 1982 (Time 2) completed mailed questionnaires about their drinking behaviors. Time 2 quitters (n = 62) had consumed no alcohol for at least the 6 months before that survey; reducers (n = 255) had decreased their yearly alcohol consumption by at least one-half. Compared to 971 controls, quitters reported more drinking problems at Time 1; reducers reported higher consumption at Time 1, which was the only factor predictive of subsequent reduction (p less than .001). Regression analyses considering contextual-motivational factors for drinking showed that at Time 1 quitters were less likely than controls to have consumed alcohol during evenings out (p = .008), in family-home settings (p = .013), or for salutary reasons (p = .084); conversely, they were more likely to have consumed alcohol to reduce negative affect (p = .011). Reducers cited more social-situational reasons for curtailing drinking; quitters cited more personal reasons related to health and alcohol effects. These findings indicate that in a community sample of men, problematic drinking behaviors tend to predict subsequent abstention rather than reduced drinking.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.15288/jsa.1988.49.363 | DOI Listing |
Am J Drug Alcohol Abuse
January 2025
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kratom is a plant with alkaloids acting at opioid, serotonergic, adrenergic, and other receptors. Consumers report numerous use motivations. To distinguish subgroups of kratom consumers by kratom-use motivations using latent-class analysis.
View Article and Find Full Text PDFBMC Gastroenterol
January 2025
Department of Nephrology, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.
Background: Gallstone disease (GSD) is associated with obesity. The Cardiometabolic Index (CMI), a metric that accurately assesses central adiposity and visceral fat, has not been extensively studied in relation to GSD risk. This study investigates the link between CMI and GSD incidence in U.
View Article and Find Full Text PDFLancet Reg Health Am
February 2025
Molecular Carcinogenesis Program, Coordination of Research and Innovation, Brazilian Nacional Cancer Institute (INCA), Rio de Janeiro, Brazil.
Background: The advanced stage of cancer is a determining factor in poor prognosis. Head and neck squamous cell carcinomas (HNSCC) are highly incident in Brazil, but similarly to many Low and Middle-Income Countries, data is limited regarding the proportion of tumours diagnosed at advanced clinical stages and the main factors associated with it. Therefore, this study aimed to identify the factors associated with advanced stage of HNSCC in Brazil.
View Article and Find Full Text PDFPublic Health
January 2025
Department of Public Health, Policy and Systems, University of Liverpool, UK. Electronic address:
Objectives: Alcohol consumption and its associated harms pose a significant challenge to public health in the UK. To address this issue, Wales implemented a Minimum Unit Price policy (MUP) in February 2020, setting a minimum price of 50p per UK unit of alcohol (10 ml/8 g). In this study we evaluate the policy's impact on alcohol sales metrics to gauge its effectiveness in improving public health outcomes.
View Article and Find Full Text PDFWorld J Hepatol
January 2025
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8520, Japan.
Hepatitis B virus (HBV) infection causes acute and chronic hepatitis, compensated and decompensated cirrhosis, and hepatocellular carcinoma worldwide. The actual status of HBV infection and its treatment in certain regions of Asian and African countries, including Ethiopia, has not been well-documented thus far. Antiviral therapy for HBV infection can prevent the progression of HBV-related liver diseases and decrease the HBV-related symptoms, such as abdominal symptoms, fatigue, systemic symptoms and others.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!